Bristol Myers Squibb CO

Bristol Myers Squibb reported strong second quarter 2026 financial results, driven by its Growth Portfolio, and raised its full-year revenue and EPS guidance.

Bristol-Myers Squibb shareholders re-elected all 11 director nominees and approved executive compensation and the 2026 incentive plan at the annual meeting.

Bristol Myers Squibb announced first quarter 2026 financial results, with total revenues reaching $11.5 billion, a 3% increase year-over-year, driven by strong performance in its Growth Portfolio.

Bristol Myers Squibb announced its Q4 and full-year 2025 financial results, showcasing robust growth in its new product portfolio despite declines in legacy assets, and provided optimistic 2026 guidance.

Bristol-Myers Squibb presented its 'Built for Growth' strategy at the J.P. Morgan Healthcare Conference, highlighting strong 2025 performance and a robust pipeline aimed at sustainable growth into the 2030s.

Bristol Myers Squibb accepted $7.22 billion in principal through amended cash tender offers, set early settlement for November 20, 2025, and expects no further acceptances.

Bristol Myers Squibb reported a 6% increase in Q2 2026 revenue to $12.97 billion and a significant rise in diluted EPS to $1.62, driven by strong performance in its Growth Portfolio and Eliquis.

Bristol Myers Squibb reported a 3% increase in total revenues for the first quarter of 2026, driven by its Growth Portfolio and Eliquis, despite generic erosion in its Legacy Portfolio.

Bristol-Myers Squibb reported a significant increase in Q3 net earnings and diluted EPS, driven by strong performance in its Growth Portfolio and strategic business development activities, despite ongoing generic erosion of legacy products.

Bristol-Myers Squibb reported a 1% increase in total revenues for Q2 2025, driven by growth in its new portfolio, but saw a decline in GAAP and non-GAAP EPS due to significant R&D investments and ongoing generic erosion of legacy products.

Bristol-Myers Squibb's Q1 2025 results show a revenue decrease of 6% despite growth in key products, impacted by generic erosion and changes in the U.S. Medicare Part D program.

Bristol-Myers Squibb's Q3 2024 results show revenue growth driven by key products, but are impacted by significant acquisition costs and restructuring charges.

Bristol-Myers Squibb reports flat 2025 revenues, with strong growth in its new portfolio offsetting declines from generic competition and increased government rebates.

Bristol-Myers Squibb's 2024 results reflect revenue growth driven by key products and strategic acquisitions, offset by generic erosion and significant IPRD expenses.

Bristol-Myers Squibb has granted restricted stock units to employees under its 2021 Stock Award and Incentive Plan, with vesting periods ranging from one to five years.

Phyllis R. Yale, a Director at Bristol Myers Squibb, reported a transaction involving deferred share units.

Theodore R. Samuels II, a Director at Bristol Myers Squibb, reported transactions involving deferred share units.

Bristol Myers Squibb Director Derica W. Rice reported transactions involving deferred share units.

Julia A. Haller, a Director at Bristol Myers Squibb, reported a transaction involving the exercise of stock options and acquisition of common stock.

EVP Wendy Short Bartie acquired 8,040 shares of Bristol Myers Squibb common stock via restricted stock unit vesting.

EVP and Chief Commercial Officer Adam Lenkowsky reported the vesting and tax-related disposition of Bristol Myers Squibb market share units.

Bristol Myers Squibb announces its 2026 Annual Meeting of Shareholders, highlighting 2025's strong Growth Portfolio sales and strategic pipeline advancements amidst executive compensation and governance proposals.

Bristol-Myers Squibb's proxy statement highlights the company's strategic priorities, including pipeline progress, commercial performance, and commitment to corporate governance, aimed at achieving sustained top-tier growth and maximizing shareholder value.

Bristol-Myers Squibb Company announces its 2025 Annual Meeting of Shareholders to be held virtually on May 6, 2025, outlining key voting items including the election of directors and executive compensation.

Bristol-Myers Squibb's 2025 proxy statement highlights the company's focus on transformational medicines, operational excellence, and strategic capital allocation to drive sustained growth and shareholder returns.

Bristol-Myers Squibb's 2024 proxy statement highlights the company's focus on R&D, business development, ESG initiatives, and sustainable growth, with a target of launching 16 new products by 2030.

Bristol-Myers Squibb Company has filed a definitive proxy statement with the SEC.

Vanguard Capital Management disclosed a beneficial ownership of 153,108,018 shares, representing 7.49% of Bristol-Myers Squibb's common stock as of March 31, 2026.

The Vanguard Group has amended its Schedule 13G filing for Bristol-Myers Squibb Co, reporting 0% beneficial ownership due to an internal realignment.

JPMorgan Chase & Co. has filed an amendment to its Schedule 13G, disclosing a 4.0% beneficial ownership stake in Bristol-Myers Squibb Company as of September 30, 2025.

JPMorgan Chase & Co. has filed a Schedule 13G, revealing a beneficial ownership of 5.1% in Bristol-Myers Squibb Company as of March 31, 2025.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 7.1% beneficial ownership stake in Bristol Myers Squibb Co. as of March 31, 2025.

Bristol Myers Squibb Company and its subsidiary Celgene Corporation have filed an amended Schedule 13G, disclosing a continued passive beneficial ownership of 1.9% in Celularity Inc.'s Class A Common Stock.